Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 1307 entries
Sorted by: Best Match Show Resources per page
Erratum to: Plasma proteolytic cascade activation during neonatal cardiopulmonary bypass surgery.

Thrombosis and haemostasis

Maroney SA, Peterson JA, Zwifelhofer W, Martinez ND, Yan K, Ra N, Stuth E, Scott JP, Bercovitz RS, Woods RK, Mast AE.
PMID: 30357781
Thromb Haemost. 2018 Nov;118(11):2009. doi: 10.1055/s-0038-1675192. Epub 2018 Oct 24.

No abstract available.

Cite
Maroney SA, Peterson JA, Zwifelhofer W, et al. Erratum to: Plasma proteolytic cascade activation during neonatal cardiopulmonary bypass surgery. Thromb Haemost. 2018;118(11):2009doi: 10.1055/s-0038-1675192.
Maroney, S. A., Peterson, J. A., Zwifelhofer, W., Martinez, N. D., Yan, K., Ra, N., Stuth, E., Scott, J. P., Bercovitz, R. S., Woods, R. K., & Mast, A. E. (2018). Erratum to: Plasma proteolytic cascade activation during neonatal cardiopulmonary bypass surgery. Thrombosis and haemostasis, 118(11), 2009. https://doi.org/10.1055/s-0038-1675192
Maroney, Susan A, et al. "Erratum to: Plasma proteolytic cascade activation during neonatal cardiopulmonary bypass surgery." Thrombosis and haemostasis vol. 118,11 (2018): 2009. doi: https://doi.org/10.1055/s-0038-1675192
Maroney SA, Peterson JA, Zwifelhofer W, Martinez ND, Yan K, Ra N, Stuth E, Scott JP, Bercovitz RS, Woods RK, Mast AE. Erratum to: Plasma proteolytic cascade activation during neonatal cardiopulmonary bypass surgery. Thromb Haemost. 2018 Nov;118(11):2009. doi: 10.1055/s-0038-1675192. Epub 2018 Oct 24. PMID: 30357781.
Copy Download .nbib Format: NLM
Hemorrhagic disorders of fibrinolysis: a clinical review.

Journal of thrombosis and haemostasis : JTH

Saes JL, Schols SEM, van Heerde WL, Nijziel MR.
PMID: 29847021
J Thromb Haemost. 2018 May 30; doi: 10.1111/jth.14160. Epub 2018 May 30.

Hyperfibrinolytic bleeding can be caused by a deficiency of one of the inhibitors of fibrinolysis (plasminogen activator inhibitor type 1 [PAI-1] or α2-antiplasmin [α2-AP]), or an excess of one of the activators of fibrinolysis: tissue-type plasminogen activator or urokinase-type...

Cite
Saes JL, Schols SEM, van Heerde WL, et al. Hemorrhagic disorders of fibrinolysis: a clinical review. J Thromb Haemost. 2018;doi: 10.1111/jth.14160.
Saes, J. L., Schols, S. E. M., van Heerde, W. L., & Nijziel, M. R. (2018). Hemorrhagic disorders of fibrinolysis: a clinical review. Journal of thrombosis and haemostasis : JTH, . https://doi.org/10.1111/jth.14160
Saes, J L, et al. "Hemorrhagic disorders of fibrinolysis: a clinical review." Journal of thrombosis and haemostasis : JTH vol. (2018). doi: https://doi.org/10.1111/jth.14160
Saes JL, Schols SEM, van Heerde WL, Nijziel MR. Hemorrhagic disorders of fibrinolysis: a clinical review. J Thromb Haemost. 2018 May 30; doi: 10.1111/jth.14160. Epub 2018 May 30. PMID: 29847021.
Copy Download .nbib Format: NLM
Erratum to: Prothrombin Complex Concentrate for Major Bleeding on Factor Xa Inhibitors: A Prospective Cohort Study.

Thrombosis and haemostasis

Schulman S, Gross PL, Ritchie B, Nahirniak S, Lin Y, Lieberman L, Carrier M, Crowther MA, Ghosh I, Lazo-Langner A, Zondag M.
PMID: 30419599
Thromb Haemost. 2018 Dec;118(12):2188. doi: 10.1055/s-0038-1675417. Epub 2018 Nov 12.

No abstract available.

Cite
Schulman S, Gross PL, Ritchie B, et al. Erratum to: Prothrombin Complex Concentrate for Major Bleeding on Factor Xa Inhibitors: A Prospective Cohort Study. Thromb Haemost. 2018;118(12):2188doi: 10.1055/s-0038-1675417.
Schulman, S., Gross, P. L., Ritchie, B., Nahirniak, S., Lin, Y., Lieberman, L., Carrier, M., Crowther, M. A., Ghosh, I., Lazo-Langner, A., Zondag, M. (2018). Erratum to: Prothrombin Complex Concentrate for Major Bleeding on Factor Xa Inhibitors: A Prospective Cohort Study. Thrombosis and haemostasis, 118(12), 2188. https://doi.org/10.1055/s-0038-1675417
Schulman, Sam, et al. "Erratum to: Prothrombin Complex Concentrate for Major Bleeding on Factor Xa Inhibitors: A Prospective Cohort Study." Thrombosis and haemostasis vol. 118,12 (2018): 2188. doi: https://doi.org/10.1055/s-0038-1675417
Schulman S, Gross PL, Ritchie B, Nahirniak S, Lin Y, Lieberman L, Carrier M, Crowther MA, Ghosh I, Lazo-Langner A, Zondag M. Erratum to: Prothrombin Complex Concentrate for Major Bleeding on Factor Xa Inhibitors: A Prospective Cohort Study. Thromb Haemost. 2018 Dec;118(12):2188. doi: 10.1055/s-0038-1675417. Epub 2018 Nov 12. PMID: 30419599.
Copy Download .nbib Format: NLM
Endothelial Cell-Specific Overexpression of Del-1 Drives Expansion of Haematopoietic Progenitor Cells in the Bone Marrow.

Thrombosis and haemostasis

Chen LS, Kourtzelis I, Singh RP, Grossklaus S, Wielockx B, Hajishengallis G, Chavakis T, Mitroulis I.
PMID: 29415284
Thromb Haemost. 2018 Feb 07; doi: 10.1055/s-0038-1624582. Epub 2018 Feb 07.

No abstract available.

Cite
Chen LS, Kourtzelis I, Singh RP, et al. Endothelial Cell-Specific Overexpression of Del-1 Drives Expansion of Haematopoietic Progenitor Cells in the Bone Marrow. Thromb Haemost. 2018;doi: 10.1055/s-0038-1624582.
Chen, L. S., Kourtzelis, I., Singh, R. P., Grossklaus, S., Wielockx, B., Hajishengallis, G., Chavakis, T., & Mitroulis, I. (2018). Endothelial Cell-Specific Overexpression of Del-1 Drives Expansion of Haematopoietic Progenitor Cells in the Bone Marrow. Thrombosis and haemostasis, . https://doi.org/10.1055/s-0038-1624582
Chen, Lan-Sun, et al. "Endothelial Cell-Specific Overexpression of Del-1 Drives Expansion of Haematopoietic Progenitor Cells in the Bone Marrow." Thrombosis and haemostasis vol. (2018). doi: https://doi.org/10.1055/s-0038-1624582
Chen LS, Kourtzelis I, Singh RP, Grossklaus S, Wielockx B, Hajishengallis G, Chavakis T, Mitroulis I. Endothelial Cell-Specific Overexpression of Del-1 Drives Expansion of Haematopoietic Progenitor Cells in the Bone Marrow. Thromb Haemost. 2018 Feb 07; doi: 10.1055/s-0038-1624582. Epub 2018 Feb 07. PMID: 29415284; PMCID: PMC6081267.
Copy Download .nbib Format: NLM
Antiviral anticoagulation.

Research and practice in thrombosis and haemostasis

Pryzdial ELG, Sutherland MR, Lin BH, Horwitz M.
PMID: 32685886
Res Pract Thromb Haemost. 2020 Jul 06;4(5):774-788. doi: 10.1002/rth2.12406. eCollection 2020 Jul.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel envelope virus that causes coronavirus disease 2019 (COVID-19). Hallmarks of COVID-19 are a puzzling form of thrombophilia that has elevated D-dimer but only modest effects on other parameters of...

Cite
Pryzdial ELG, Sutherland MR, Lin BH, et al. Antiviral anticoagulation. Res Pract Thromb Haemost. 2020;4(5):774-788doi: 10.1002/rth2.12406.
Pryzdial, E. L. G., Sutherland, M. R., Lin, B. H., & Horwitz, M. (2020). Antiviral anticoagulation. Research and practice in thrombosis and haemostasis, 4(5), 774-788. https://doi.org/10.1002/rth2.12406
Pryzdial, Edward L G, et al. "Antiviral anticoagulation." Research and practice in thrombosis and haemostasis vol. 4,5 (2020): 774-788. doi: https://doi.org/10.1002/rth2.12406
Pryzdial ELG, Sutherland MR, Lin BH, Horwitz M. Antiviral anticoagulation. Res Pract Thromb Haemost. 2020 Jul 06;4(5):774-788. doi: 10.1002/rth2.12406. eCollection 2020 Jul. PMID: 32685886; PMCID: PMC7354393.
Copy Download .nbib Format: NLM
Bleeding is increased in amyloid precursor protein knockout mouse.

Research and practice in thrombosis and haemostasis

Mazinani N, Strilchuk AW, Baylis JR, Hur WS, Jefferies WA, Kastrup CJ.
PMID: 32685890
Res Pract Thromb Haemost. 2020 Jun 14;4(5):823-828. doi: 10.1002/rth2.12375. eCollection 2020 Jul.

BACKGROUND: Amyloid precursor protein (APP) is highly expressed in platelets. APP is the precursor to amyloid beta (Aβ) peptides that accumulate in cerebral amyloid angiopathy and plaques in Alzheimer disease. APP and its metabolites interact with many components of...

Cite
Mazinani N, Strilchuk AW, Baylis JR, et al. Bleeding is increased in amyloid precursor protein knockout mouse. Res Pract Thromb Haemost. 2020;4(5):823-828doi: 10.1002/rth2.12375.
Mazinani, N., Strilchuk, A. W., Baylis, J. R., Hur, W. S., Jefferies, W. A., & Kastrup, C. J. (2020). Bleeding is increased in amyloid precursor protein knockout mouse. Research and practice in thrombosis and haemostasis, 4(5), 823-828. https://doi.org/10.1002/rth2.12375
Mazinani, Nima, et al. "Bleeding is increased in amyloid precursor protein knockout mouse." Research and practice in thrombosis and haemostasis vol. 4,5 (2020): 823-828. doi: https://doi.org/10.1002/rth2.12375
Mazinani N, Strilchuk AW, Baylis JR, Hur WS, Jefferies WA, Kastrup CJ. Bleeding is increased in amyloid precursor protein knockout mouse. Res Pract Thromb Haemost. 2020 Jun 14;4(5):823-828. doi: 10.1002/rth2.12375. eCollection 2020 Jul. PMID: 32685890; PMCID: PMC7354397.
Copy Download .nbib Format: NLM
N-Methyl-3,4-methylendioxymethamphetamine (MDMA)-related coagulopathy and rhabdomyolysis: A case series and literature review.

Research and practice in thrombosis and haemostasis

Doyle AJ, Meyer J, Breen K, Hunt BJ.
PMID: 32685891
Res Pract Thromb Haemost. 2020 Jun 14;4(5):829-834. doi: 10.1002/rth2.12360. eCollection 2020 Jul.

Coagulation changes, thrombosis, and hemorrhage have been described in patients following N-methyl-3,4-methylenedioxymethylamphetamine (MDMA) intoxication who subsequently developed serotonin syndrome and rhabdomyolysis. The clinical features and mechanism of this remain poorly described. We describe 5 sequential cases admitted to critical...

Cite
Doyle AJ, Meyer J, Breen K, et al. N-Methyl-3,4-methylendioxymethamphetamine (MDMA)-related coagulopathy and rhabdomyolysis: A case series and literature review. Res Pract Thromb Haemost. 2020;4(5):829-834doi: 10.1002/rth2.12360.
Doyle, A. J., Meyer, J., Breen, K., & Hunt, B. J. (2020). N-Methyl-3,4-methylendioxymethamphetamine (MDMA)-related coagulopathy and rhabdomyolysis: A case series and literature review. Research and practice in thrombosis and haemostasis, 4(5), 829-834. https://doi.org/10.1002/rth2.12360
Doyle, Andrew J, et al. "N-Methyl-3,4-methylendioxymethamphetamine (MDMA)-related coagulopathy and rhabdomyolysis: A case series and literature review." Research and practice in thrombosis and haemostasis vol. 4,5 (2020): 829-834. doi: https://doi.org/10.1002/rth2.12360
Doyle AJ, Meyer J, Breen K, Hunt BJ. N-Methyl-3,4-methylendioxymethamphetamine (MDMA)-related coagulopathy and rhabdomyolysis: A case series and literature review. Res Pract Thromb Haemost. 2020 Jun 14;4(5):829-834. doi: 10.1002/rth2.12360. eCollection 2020 Jul. PMID: 32685891; PMCID: PMC7354411.
Copy Download .nbib Format: NLM
Effect of pH on thrombin activity measured by calibrated automated thrombinography.

Research and practice in thrombosis and haemostasis

Jackson JW, Surov SS, Liang Y, Parunov LA, Ovanesov MV.
PMID: 32685907
Res Pract Thromb Haemost. 2020 Jun 12;4(5):944-945. doi: 10.1002/rth2.12370. eCollection 2020 Jul.

No abstract available.

Cite
Jackson JW, Surov SS, Liang Y, et al. Effect of pH on thrombin activity measured by calibrated automated thrombinography. Res Pract Thromb Haemost. 2020;4(5):944-945doi: 10.1002/rth2.12370.
Jackson, J. W., Surov, S. S., Liang, Y., Parunov, L. A., & Ovanesov, M. V. (2020). Effect of pH on thrombin activity measured by calibrated automated thrombinography. Research and practice in thrombosis and haemostasis, 4(5), 944-945. https://doi.org/10.1002/rth2.12370
Jackson, Joseph W, et al. "Effect of pH on thrombin activity measured by calibrated automated thrombinography." Research and practice in thrombosis and haemostasis vol. 4,5 (2020): 944-945. doi: https://doi.org/10.1002/rth2.12370
Jackson JW, Surov SS, Liang Y, Parunov LA, Ovanesov MV. Effect of pH on thrombin activity measured by calibrated automated thrombinography. Res Pract Thromb Haemost. 2020 Jun 12;4(5):944-945. doi: 10.1002/rth2.12370. eCollection 2020 Jul. PMID: 32685907; PMCID: PMC7354418.
Copy Download .nbib Format: NLM
Migraine and venous thrombosis: Another important piece of the puzzle.

Research and practice in thrombosis and haemostasis

Siegerink B, Adelborg K.
PMID: 31294316
Res Pract Thromb Haemost. 2019 May 12;3(3):309-311. doi: 10.1002/rth2.12209. eCollection 2019 Jul.

No abstract available.

Cite
Siegerink B, Adelborg K. Migraine and venous thrombosis: Another important piece of the puzzle. Res Pract Thromb Haemost. 2019;3(3):309-311doi: 10.1002/rth2.12209.
Siegerink, B., & Adelborg, K. (2019). Migraine and venous thrombosis: Another important piece of the puzzle. Research and practice in thrombosis and haemostasis, 3(3), 309-311. https://doi.org/10.1002/rth2.12209
Siegerink, Bob, and Adelborg, Kasper. "Migraine and venous thrombosis: Another important piece of the puzzle." Research and practice in thrombosis and haemostasis vol. 3,3 (2019): 309-311. doi: https://doi.org/10.1002/rth2.12209
Siegerink B, Adelborg K. Migraine and venous thrombosis: Another important piece of the puzzle. Res Pract Thromb Haemost. 2019 May 12;3(3):309-311. doi: 10.1002/rth2.12209. eCollection 2019 Jul. PMID: 31294316; PMCID: PMC6611363.
Copy Download .nbib Format: NLM
Meta-analysis: Key features, potentials and misunderstandings.

Research and practice in thrombosis and haemostasis

Dekkers OM.
PMID: 30349883
Res Pract Thromb Haemost. 2018 Oct 03;2(4):658-663. doi: 10.1002/rth2.12153. eCollection 2018 Oct.

A meta-analysis consists of a systematic approach to combine different studies in one design. Preferably, a protocol is written and published spelling out the research question, eligibility criteria, risk of bias assessment, and statistical approach. Included studies are likely...

Cite
Dekkers OM. Meta-analysis: Key features, potentials and misunderstandings. Res Pract Thromb Haemost. 2018;2(4):658-663doi: 10.1002/rth2.12153.
Dekkers, O. M. (2018). Meta-analysis: Key features, potentials and misunderstandings. Research and practice in thrombosis and haemostasis, 2(4), 658-663. https://doi.org/10.1002/rth2.12153
Dekkers, Olaf M. "Meta-analysis: Key features, potentials and misunderstandings." Research and practice in thrombosis and haemostasis vol. 2,4 (2018): 658-663. doi: https://doi.org/10.1002/rth2.12153
Dekkers OM. Meta-analysis: Key features, potentials and misunderstandings. Res Pract Thromb Haemost. 2018 Oct 03;2(4):658-663. doi: 10.1002/rth2.12153. eCollection 2018 Oct. PMID: 30349883; PMCID: PMC6178740.
Copy Download .nbib Format: NLM
Management of anticoagulation for cancer-associated thrombosis in patients with thrombocytopenia: A systematic review.

Research and practice in thrombosis and haemostasis

Samuelson Bannow BR, Lee AYY, Khorana AA, Zwicker JI, Noble S, Ay C, Carrier M.
PMID: 30349884
Res Pract Thromb Haemost. 2018 Jun 19;2(4):664-669. doi: 10.1002/rth2.12111. eCollection 2018 Oct.

BACKGROUND: The management of anticoagulation for cancer-associated thrombosis (CAT) in patients with thrombocytopenia is controversial. Whereas some studies suggest that administration of reduced-dose low-molecular-weight heparin (LMWH) or temporary discontinuation for moderate and severe thrombocytopenia may be a safe and...

Cite
Samuelson Bannow BR, Lee AYY, Khorana AA, et al. Management of anticoagulation for cancer-associated thrombosis in patients with thrombocytopenia: A systematic review. Res Pract Thromb Haemost. 2018;2(4):664-669doi: 10.1002/rth2.12111.
Samuelson Bannow, B. R., Lee, A. Y. Y., Khorana, A. A., Zwicker, J. I., Noble, S., Ay, C., & Carrier, M. (2018). Management of anticoagulation for cancer-associated thrombosis in patients with thrombocytopenia: A systematic review. Research and practice in thrombosis and haemostasis, 2(4), 664-669. https://doi.org/10.1002/rth2.12111
Samuelson Bannow, Bethany R, et al. "Management of anticoagulation for cancer-associated thrombosis in patients with thrombocytopenia: A systematic review." Research and practice in thrombosis and haemostasis vol. 2,4 (2018): 664-669. doi: https://doi.org/10.1002/rth2.12111
Samuelson Bannow BR, Lee AYY, Khorana AA, Zwicker JI, Noble S, Ay C, Carrier M. Management of anticoagulation for cancer-associated thrombosis in patients with thrombocytopenia: A systematic review. Res Pract Thromb Haemost. 2018 Jun 19;2(4):664-669. doi: 10.1002/rth2.12111. eCollection 2018 Oct. PMID: 30349884; PMCID: PMC6178713.
Copy Download .nbib Format: NLM
Peak plasma concentration of direct oral anticoagulants in obese patients weighing over 120 kilograms: A retrospective study.

Research and practice in thrombosis and haemostasis

Piran S, Traquair H, Chan N, Bhagirath V, Schulman S.
PMID: 30349887
Res Pract Thromb Haemost. 2018 Aug 29;2(4):684-688. doi: 10.1002/rth2.12146. eCollection 2018 Oct.

BACKGROUND: Due to a paucity of data on the efficacy and safety of direct oral anticoagulants (DOACs) in patients with a body mass index >40 kg/mOBJECTIVES: To determine the proportion of obese patients with body weight >120 kg with...

Cite
Piran S, Traquair H, Chan N, et al. Peak plasma concentration of direct oral anticoagulants in obese patients weighing over 120 kilograms: A retrospective study. Res Pract Thromb Haemost. 2018;2(4):684-688doi: 10.1002/rth2.12146.
Piran, S., Traquair, H., Chan, N., Bhagirath, V., & Schulman, S. (2018). Peak plasma concentration of direct oral anticoagulants in obese patients weighing over 120 kilograms: A retrospective study. Research and practice in thrombosis and haemostasis, 2(4), 684-688. https://doi.org/10.1002/rth2.12146
Piran, Siavash, et al. "Peak plasma concentration of direct oral anticoagulants in obese patients weighing over 120 kilograms: A retrospective study." Research and practice in thrombosis and haemostasis vol. 2,4 (2018): 684-688. doi: https://doi.org/10.1002/rth2.12146
Piran S, Traquair H, Chan N, Bhagirath V, Schulman S. Peak plasma concentration of direct oral anticoagulants in obese patients weighing over 120 kilograms: A retrospective study. Res Pract Thromb Haemost. 2018 Aug 29;2(4):684-688. doi: 10.1002/rth2.12146. eCollection 2018 Oct. PMID: 30349887; PMCID: PMC6178753.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 1307 entries